Loading…

Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening

Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1993-03, Vol.71 (6), p.1982-1988
Main Authors: Järvisalo, Jorma, Hakama, Matti, Knekt, Paul, Stenman, Ulf‐Håkan, Leino, Aila, Teppo, Lyly, Maatela, Jouni, Aromaa, Arpo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03
container_end_page 1988
container_issue 6
container_start_page 1982
container_title Cancer
container_volume 71
creator Järvisalo, Jorma
Hakama, Matti
Knekt, Paul
Stenman, Ulf‐Håkan
Leino, Aila
Teppo, Lyly
Maatela, Jouni
Aromaa, Arpo
description Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records. Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking. Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.
doi_str_mv 10.1002/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75603073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75603073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</originalsourceid><addsrcrecordid>eNqVkF1r2zAYhcVY6bJuP2GgizE2iLNXH5albAyMl6aB0sCawWAXL7IsF2-200k1o_9-DkkD3cVgV0KcR4ejh5CCwYwB8PcMTJYAk_wtM0aAYOm7jM3VR2Y0n8_z1eekuCq-cM0hY6AYfBIzmBXrDzxZPiGT4-unZAIAOkml-PaMPI_xx3jNeCpOyamWUmTSTMj5tQ9DR--GbhtoZ8NPHyItFvmUFjlNYUo3-WY1pbav6NX1gjY9bYf-hjrbOx9odMH7vulvXpCT2rbRvzycZ-Tr-WJTXCSX6-WqyC8TJ5mEhDld2pSDr5ThqXGiVqlStQHNXcX4mJZCCK1KkBXYOmOm5FowbWrNbVmCOCNv9r23Yftr8PEOuyY637a299shYpYqEJCJEfy-B13Yxhh8jbehGf93jwxwZxl3nnDnCR8sY8ZQ4c4y4mgZH1tGgYDFGjkux_ZXhxlD2fnq2H3QOuavD7mNzrZ1GHU18YhJJRnIdMTqPfa7af39_y3858C_EvEHiTSiQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75603073</pqid></control><display><type>article</type><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</creator><creatorcontrib>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</creatorcontrib><description>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records. Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking. Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930315)71:6&lt;1982::AID-CNCR2820710610&gt;3.0.CO;2-G</identifier><identifier>PMID: 8443749</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antigens, Tumor-Associated, Carbohydrate - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; CA 50 ; carcinoembryonic antigen ; Carcinoembryonic Antigen - blood ; Female ; human serum ; Humans ; lung cancer screening ; Lung Neoplasms - blood ; Male ; Medical sciences ; neuron‐specific enolase ; Phosphopyruvate Hydratase - blood ; Pneumology ; register linkage study ; Sensitivity and Specificity ; Trypsin Inhibitor, Kazal Pancreatic - blood ; tumor markers ; Tumors of the respiratory system and mediastinum ; tumor‐associated trypsin inhibitor</subject><ispartof>Cancer, 1993-03, Vol.71 (6), p.1982-1988</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4641045$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8443749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Järvisalo, Jorma</creatorcontrib><creatorcontrib>Hakama, Matti</creatorcontrib><creatorcontrib>Knekt, Paul</creatorcontrib><creatorcontrib>Stenman, Ulf‐Håkan</creatorcontrib><creatorcontrib>Leino, Aila</creatorcontrib><creatorcontrib>Teppo, Lyly</creatorcontrib><creatorcontrib>Maatela, Jouni</creatorcontrib><creatorcontrib>Aromaa, Arpo</creatorcontrib><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records. Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking. Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</description><subject>Antigens, Tumor-Associated, Carbohydrate - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA 50</subject><subject>carcinoembryonic antigen</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Female</subject><subject>human serum</subject><subject>Humans</subject><subject>lung cancer screening</subject><subject>Lung Neoplasms - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>neuron‐specific enolase</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Pneumology</subject><subject>register linkage study</subject><subject>Sensitivity and Specificity</subject><subject>Trypsin Inhibitor, Kazal Pancreatic - blood</subject><subject>tumor markers</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>tumor‐associated trypsin inhibitor</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNqVkF1r2zAYhcVY6bJuP2GgizE2iLNXH5albAyMl6aB0sCawWAXL7IsF2-200k1o_9-DkkD3cVgV0KcR4ejh5CCwYwB8PcMTJYAk_wtM0aAYOm7jM3VR2Y0n8_z1eekuCq-cM0hY6AYfBIzmBXrDzxZPiGT4-unZAIAOkml-PaMPI_xx3jNeCpOyamWUmTSTMj5tQ9DR--GbhtoZ8NPHyItFvmUFjlNYUo3-WY1pbav6NX1gjY9bYf-hjrbOx9odMH7vulvXpCT2rbRvzycZ-Tr-WJTXCSX6-WqyC8TJ5mEhDld2pSDr5ThqXGiVqlStQHNXcX4mJZCCK1KkBXYOmOm5FowbWrNbVmCOCNv9r23Yftr8PEOuyY637a299shYpYqEJCJEfy-B13Yxhh8jbehGf93jwxwZxl3nnDnCR8sY8ZQ4c4y4mgZH1tGgYDFGjkux_ZXhxlD2fnq2H3QOuavD7mNzrZ1GHU18YhJJRnIdMTqPfa7af39_y3858C_EvEHiTSiQA</recordid><startdate>19930315</startdate><enddate>19930315</enddate><creator>Järvisalo, Jorma</creator><creator>Hakama, Matti</creator><creator>Knekt, Paul</creator><creator>Stenman, Ulf‐Håkan</creator><creator>Leino, Aila</creator><creator>Teppo, Lyly</creator><creator>Maatela, Jouni</creator><creator>Aromaa, Arpo</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930315</creationdate><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><author>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antigens, Tumor-Associated, Carbohydrate - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA 50</topic><topic>carcinoembryonic antigen</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Female</topic><topic>human serum</topic><topic>Humans</topic><topic>lung cancer screening</topic><topic>Lung Neoplasms - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>neuron‐specific enolase</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Pneumology</topic><topic>register linkage study</topic><topic>Sensitivity and Specificity</topic><topic>Trypsin Inhibitor, Kazal Pancreatic - blood</topic><topic>tumor markers</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>tumor‐associated trypsin inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Järvisalo, Jorma</creatorcontrib><creatorcontrib>Hakama, Matti</creatorcontrib><creatorcontrib>Knekt, Paul</creatorcontrib><creatorcontrib>Stenman, Ulf‐Håkan</creatorcontrib><creatorcontrib>Leino, Aila</creatorcontrib><creatorcontrib>Teppo, Lyly</creatorcontrib><creatorcontrib>Maatela, Jouni</creatorcontrib><creatorcontrib>Aromaa, Arpo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Järvisalo, Jorma</au><au>Hakama, Matti</au><au>Knekt, Paul</au><au>Stenman, Ulf‐Håkan</au><au>Leino, Aila</au><au>Teppo, Lyly</au><au>Maatela, Jouni</au><au>Aromaa, Arpo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-03-15</date><risdate>1993</risdate><volume>71</volume><issue>6</issue><spage>1982</spage><epage>1988</epage><pages>1982-1988</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records. Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking. Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8443749</pmid><doi>10.1002/1097-0142(19930315)71:6&lt;1982::AID-CNCR2820710610&gt;3.0.CO;2-G</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1993-03, Vol.71 (6), p.1982-1988
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_75603073
source Free E-Journal (出版社公開部分のみ)
subjects Antigens, Tumor-Associated, Carbohydrate - blood
Biological and medical sciences
Biomarkers, Tumor - blood
CA 50
carcinoembryonic antigen
Carcinoembryonic Antigen - blood
Female
human serum
Humans
lung cancer screening
Lung Neoplasms - blood
Male
Medical sciences
neuron‐specific enolase
Phosphopyruvate Hydratase - blood
Pneumology
register linkage study
Sensitivity and Specificity
Trypsin Inhibitor, Kazal Pancreatic - blood
tumor markers
Tumors of the respiratory system and mediastinum
tumor‐associated trypsin inhibitor
title Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A41%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20tumor%20markers%20CEA,%20CA%2050,%20TATI,%20and%20NSE%20in%20lung%20cancer%20screening&rft.jtitle=Cancer&rft.au=J%C3%A4rvisalo,%20Jorma&rft.date=1993-03-15&rft.volume=71&rft.issue=6&rft.spage=1982&rft.epage=1988&rft.pages=1982-1988&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19930315)71:6%3C1982::AID-CNCR2820710610%3E3.0.CO;2-G&rft_dat=%3Cproquest_cross%3E75603073%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75603073&rft_id=info:pmid/8443749&rfr_iscdi=true